A single arm, two center, phase II study of RAD001 [everolimus] in patients with metastatic, hormone-refractory prostate cancer

Trial Profile

A single arm, two center, phase II study of RAD001 [everolimus] in patients with metastatic, hormone-refractory prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 May 2012 Actual patient number is 47 according to ClinicalTrials.gov.
    • 15 May 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top